Results 11 to 20 of about 798,481 (288)

Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers

Contemporary Oncology, 2020
The phosphoinositide 3-kinase (PI3K) pathway is an important regulator of cell proliferation and metabolism. PI3K activation initiates a signal transduction cascade, of which the major effectors are the kinases AKT and mTOR.
Ilham Kandoussi, Oussama Benherrif, Wiame Lakhlili, Jamal Taoufik, Azeddine Ibrahimi   +4 more
doaj   +2 more sources

Inhibitors of mTOR [PDF]

The Oncologist, 2010
Inhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies.
Howard Gurney, Jan H.M. Schellens, Schellens, Jan H. M., Klümpen, Heinz-Josef, Gurney, Howard, Heinz-Josef Klümpen, Beijnen, Jos H., Jos H. Beijnen   +7 more
core   +4 more sources

Differential expression of mTOR signalling components in drug resistance in ovarian cancer [PDF]

, 2010
This article has been made available through the Brunel Open Access Publishing Fund and is available from the specified link - Copyright @ 2010 The International Institute of Anticancer Research.Background/Aim: A limitation to successful cancer ...
Karteris, E, Foster, H, Goumenou, A, Pados, G, Harvey, AJ, Coley, HM   +5 more
core   +7 more sources

Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes

Breast Cancer: Targets and Therapy, 2014
Guy Jerusalem, Andree Rorive, Joelle Collignon Medical Oncology, CHU Sart Tilman Liege, Domaine Universitaire du Sart Tilman, Liege, Belgium Abstract: Many systemic treatment options are available for advanced breast cancer, including endocrine therapy,
Jerusalem G, Rorive A, Collignon J
doaj   +1 more source

ATP-competitive inhibitors of mTOR: an update.

Current Medicinal Chemistry, 2011
mTOR (mammalian target of rapamycin) is a serine-threonine kinase belonging to the PI3K/Akt/mTOR signalling pathway that is involved in several cell functions, including growth, proliferation, apoptosis and autophagy.
BRULLO, CHIARA, Radi M, SCHENONE, SILVIA, MUSUMECI, FRANCESCA, Botta M.   +4 more
core   +7 more sources

Updates of mTOR Inhibitors [PDF]

Anti-Cancer Agents in Medicinal Chemistry, 2010
Mammalian target of rapamycin (mTOR) is a central controller of cell growth, proliferation, metabolism and angiogenesis. mTOR signaling is often dysregulated in various human diseases and thus attracts great interest in developing drugs that target mTOR.
Hongyu, Zhou, Yan, Luo, Shile, Huang
openaire   +2 more sources

mTOR inhibitors: An overview [PDF]

Liver Transplantation, 2001
Inhibitors of the mammalian target of rapamycin are a new class of immunosuppressants. In contrast to other macrolides, such as tacrolimus and cyclosporine A, they do not inhibit calcineurin and thus signal I of T-cell activation.
P, Neuhaus, J, Klupp, J M, Langrehr
openaire   +2 more sources

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia [PDF]

, 2013
Purpose: Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase ...
Oliver G Ottmann, Martin Ruthardt, Oliver G. Ottmann, Oliver G. Ottmann (485229), Falkenburg, J.H.F., Marcus Liebermann (485228), Bart A. Nijmeijer (485227), Pfeifer, Heike, Falkenburg, J. H. Frederik, J. H. Frederik Falkenburg, Ruthardt, Martin, Tamara Tesanovic, Tesanovic, Tamara, Bart A Nijmeijer, Heike Pfeifer, Ottmann, Oliver G., Susanne Badura (485223), Sylvia Wystub, Sylvia Wystub (485226), Liebermann, M., Marcus Liebermann, Bart A. Nijmeijer, Ottmann, O.G., Nijmeijer, Bart A., Badura, S., Susanne Badura, Wystub, Sylvia, Pfeifer, H., J H Frederik Falkenburg, Tamara Tesanovic (485224), Martin Ruthardt (66634), Wystub, S., Nijmeijer, B.A., Ruthardt, M., Tesanovic, T., Badura, Susanne, Heike Pfeifer (485225), J. H. Frederik Falkenburg (210432), Liebermann, Marcus   +38 more
core   +1 more source

Targeting ganglioneuromas with mTOR inhibitors [PDF]

Molecular & Cellular Oncology, 2021
We recently identified activated protein kinase B (PKB/AKT) as a tumorigenic driver in childhood ganglioneuroma. Inhibition of the mechanistic target of rapamycin (mTOR), a serine/threonine kinase downstream of AKT, effectively reduced the tumor burden in zebrafish with ganglioneuroma. We propose a clinical trial of mTOR inhibitors as a means to shrink
Ting Tao, Hui Shi, Adam D. Durbin, A. Thomas Look   +3 more
openaire   +3 more sources

Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling [PDF]

, 2012
Many cellular processes including apoptosis, autophagy, translation, energy metabolism, and inflammation are controlled by the mammalian target of rapamycin (mTOR) kinase and the endoplasmic reticulum (ER) stress pathway, also known as the unfolded ...
Appenzeller-Herzog, Christian, Hall, Michael N.   +1 more
core   +1 more source